Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | CAMK2A | Q9UQM7 | 5/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943843 | 0.85 | RXRA (0.63) | RXRARXRBCAMK2ARXRGNPSR1 | |
| SCHEMBL28346847 | 0.84 | HSD17B1 (0.47) | RXRARXRBRXRGNPSR1ALDH1A1 | |
| SCHEMBL1257788 | 0.82 | SRC (0.62) | RXRARXRBRXRGNPSR1ALDH1A1 | |
| SCHEMBL29419312 | 0.81 | TYR (0.60) | CAMK2ANPSR1ALDH1A1LMNAGLA | |
| SCHEMBL156238 | 0.81 | TYR (0.60) | CAMK2ANPSR1ALDH1A1LMNAGLA | |
| SCHEMBL7102470 | 0.81 | NPSR1 (0.66) | RXRARXRBRXRGNPSR1ALDH1A1 | |
| SCHEMBL2283410 | 0.80 | RXRA (0.53) | RXRARXRBCAMK2ARXRGNPSR1 | |
| Hydrochloric Acid SCHEMBL2530248 | 0.80 | SRC (0.61) | RXRARXRBRXRGNPSR1ALDH1A1 | |
| SCHEMBL12988424 | 0.79 | AIMP2 (0.40) | RXRARXRBNPSR1CA2 | |
| SCHEMBL3922071 | 0.79 | EGFR (0.52) | ALDH1A1GLAHPGDCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4515970-A | Process for preparation of alkanoic acids | SOCIETE FRANCAISE HOECHST (FR) | 1985-05-07 | — | — | US | claimed |
| EP-3125880-B1 | COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE FOR PREVENTING ACNE SCARS | GALDERMA RES & DEV (FR) | 2019-11-20 | — | — | EP | disclosed |
| EP-2563357-B1 | ADAPALENE 0.3% FOR USE IN A METHOD FOR TREATING SCARS | GALDERMA RES & DEV (FR) | 2018-10-17 | — | — | EP | disclosed |
| US-20180214401-A1 | METHOD FOR TREATING SCARS WITH ADAPALENE 0.3% | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-08-02 | — | — | US | disclosed |
| EP-3125880-A1 | COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE SCARS | Galderma Research & Development (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170020833-A1 | METHOD FOR TREATING AND/OR PREVENTING ACNE SCARS WITH A FIXED COMBINATION OF ADAPALENE OR ITS SALTS AND BENZOYL PEROXIDE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150332-A1 | COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE SCARS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-10-08 | — | — | WO | disclosed |
| EP-2563357-A1 | METHOD FOR TREATING SCARS WITH ADAPALENE 0.3% | Galderma Research & Development (FR) | 2013-03-06 | — | — | EP | disclosed |
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| WO-2011135090-A1 | METHOD FOR TREATING SCARS WITH ADAPALENE 0.3% | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-03 | — | — | WO | disclosed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |
| US-4515970-A | Process for preparation of alkanoic acids | SOCIETE FRANCAISE HOECHST (FR) | 1985-05-07 | — | — | US | disclosed |
| EP-0062440-A1 | Process for preparing phenylalkanoic acids and derivatives of benzoxazole therefrom | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | RXRA 4543/4885RXRB 4453/4885CAMK2A 3711/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | RXRA 4477/4885RXRB 4412/4885CAMK2A 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.